QualityStocks would like to highlight Boston Therapeutics, Inc. (OTCBB: BTHE), a pharmaceutical company focused on the development, manufacture, and commercialization of novel compounds to address unmet medical needs in the areas of diabetes and inflammatory diseases. The company's products are based on a platform of applied complex carbohydrate chemistry in pharmaceutical and over-the-counter products.
In the company’s news yesterday,
Boston Therapeutics announced that Mr. Jonathan B. Rome has been named as its Chief Operating Officer.
David Platt, Ph.D., Boston’s CEO, remarked, “Jonathan Rome has more than 30 years’ experience and success in the sales, marketing and distribution of pharmaceutical products and developing collaborations around the world. Jonathan is an excellent choice to commercialize SUGARDOWN® and to lead the filing of an ANDA to market BTI-7.”
Mr. Rome was the Founder, President, and CEO of ThePharmaNetwork, LLC, which was focused on pharmaceutical portfolio development, licensing, sales, marketing, and distribution of pharmaceuticals and APIs as well as sales, marketing, and distribution of finished products under the Ascend Laboratories, LLC label to all major U.S. customers. Mr. Rome was also a founder of Beijing-based AlliancePharm LLC, a founder of Shanghai-based TPN China, Inc., and a founder of Rome, Italy-based TPN Italia. Mr. Rome specializes in collaborations, global supply chain, sales and marketing, licensing, and has extensive outsourcing experience through a network that spans five continents.
“I am excited about joining Boston Therapeutics,” said Jonathan Rome. “The elements for success are here: excellent complex carbohydrate chemistry, products to address unmet medical needs in a very large diabetes market worldwide and a talented and dedicated team. I am confident we can be successful and take the Company to the next level.”
Mr. Rome will be in charge of accelerating the commercialization of SUGARDOWN® and filing an Abbreviated New Drug Application (“ANDA”) for BTI-7, a new chewable dosage form of the diabetes drug metformin hydrochloride. SUGARDOWN® is a non-systemic chewable dietary supplement tablet that controls post-meal blood glucose.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
